產(chǎn)品名稱 VX 770 - Ivacaftor | Kalydeco
產(chǎn)品貨號(hào) Axon 2503 CAS [873054-44-5] MF C24H28N2O3MW 392.49 Purity: 99% Soluble in DMSO Description Orally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels. KEYWORDS: VX 770 | supplier | CFTR potentiator | Ivacaftor | Kalydeco | VX770 | [873054-44-5] | [1174930-71-2] | Ion Channel | Cystic Fibrosis | CF | FDA-approved | ATP-independent
產(chǎn)品價(jià)格 現(xiàn)貨詢價(jià)，電話：010-67529703
產(chǎn)品規(guī)格
產(chǎn)品品牌 axonmedchem
產(chǎn)品概述
產(chǎn)品詳情

VX 770 - Ivacaftor | Kalydeco

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 2503

CAS [873054-44-5]

MF C24H28N2O3
MW 392.49

  • Purity: 99%
  • Soluble in DMSO

VX 770

Description

Orally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels.

KEYWORDS: VX 770 | supplier | CFTR potentiator | Ivacaftor | Kalydeco | VX770 | [873054-44-5] | [1174930-71-2] | Ion Channel | Cystic Fibrosis | CF | FDA-approved | ATP-independent
產(chǎn)品資料